U.S. FDA approves Roche bleeding disorder drug
New Delhi: Roche has recently received approval from U.S. regulators for its haemophilia A drug Hemlibra for use in nearly all patients, as the Swiss drugmaker pushes deeper into diseases beyond cancer to replace revenue from older, patent-expired drugs.
Hemlibra was first approved in November for adults and children with haemophilia A with factor VIII inhibitors.
The injectable medicine that helps blood to clot in patients with the genetic disorder had previously been approved in the United States and Europe for those who had developed resistance, called inhibitors, to older treatments.
Read Also: With new blood test, Roche dives deeper into personal cancer care
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd